HIV Detail Information
Cabotegravir (ID: DG00116) Resistance Data of HIV
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||||||||||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Resistant Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Resistant Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q181H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Resistant Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Resistant Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q182H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Resistant Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Resistant Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q183H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Resistant Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Resistant Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q184H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Resistant Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Resistant Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q185H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||||||||||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Sensitive Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Sensitive Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q167H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Sensitive Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Sensitive Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q168H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Sensitive Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Sensitive Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q169H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Sensitive Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Sensitive Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q170H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Sensitive Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Sensitive Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q171H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Sensitive Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Sensitive Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q172H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Sensitive Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Sensitive Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q173H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Sensitive Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Sensitive Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q174H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Sensitive Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Sensitive Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q175H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Sensitive Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Sensitive Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q176H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Sensitive Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Sensitive Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q177H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Sensitive Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Sensitive Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q178H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Sensitive Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Sensitive Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q179H/k/R plus one to two additional INSTI mutations. | |||||||||||||
Key Molecule: HIV1 Integrase (HIV1 IT) | ||||||||||||||
Sensitive Disease | Human immunodeficiency virus infection [ICD-11: 1C62.0] | |||||||||||||
Molecule Alteration |
|
|||||||||||||
Sensitive Drug | Cabotegravir | |||||||||||||
Experimental Note | Identified from the Human Clinical Data | |||||||||||||
In Vitro Model | TZM-bl cells | Uterus | Homo sapiens (Human) | CVCL_B478 | ||||||||||
Experiment for Molecule Alteration |
Population sequencing of the integrase region assay | |||||||||||||
Experiment for Drug Resistance |
TZM-bl cell line-based phenotypic assay | |||||||||||||
Mechanism Description | In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q180H/k/R plus one to two additional INSTI mutations. | |||||||||||||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.